Floatz logo

Setmelanotide

Obesity Disorder

Massachusetts General Hospitalprotein_peptidePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
59/ 100

Competitive context

464 Active assets in the Obesity Disorder cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Deoxycholic Acid
University of California, San Diego
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB

View all 50 →

Same molecule, other indications

Setmelanotide is also rated in:

Bardet-Biedl syndromeDormant
A
Indicative ·
81 / 100
View asset →
Alstrom syndromeDormant
BBB
Indicative ·
75 / 100
View asset →
inherited obesityDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →